Prelude Therapeutics Inc (PRLD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.46+4.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PRLD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 69.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PRLD — debt issuance
Dated 2026-04-21
Entry into a Material Definitive Agreement. On April 20, 2026, Prelude Therapeutics Incorporated (“Prelude”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Evercore Group L.L.C. as representatives (the “Representatives”) of the underwriters named therein, pursuant to which Prelude agreed to issue and sell an aggregate of (a) 18,018,014 shares of its voting common stock, par value $0.0001 per share (the “Common Stock”), at a price of $4.4…
Why it matters: Starting this study is a major milestone for Prelude's KAT6A degrader program. It signals progress in treating HR+ breast cancer.
Supportive ifThe Phase 1 study of PRT13722 begins as planned in Q4 2026.
Worry ifThe Phase 1 study initiation is postponed beyond Q4 2026.
Why it matters: Earnings reports provide updates on financial health and progress. They can influence investor sentiment.
Watch forEarnings report shows revenue growth and positive outlook.
Also watch forThe earnings report shows lower revenue or a bad outlook.
Why it matters: Updates on cash runway are important for funding ongoing R&D. The company needs to ensure it can support its projects.
Watch forThe company says cash runway lasts until Q2 2028 after the offering.
Also watch forThe company changes cash runway guidance to a shorter timeline.
Why it matters: Good preclinical data can raise confidence in PRT13722's potential. It can also attract investor interest.
Supportive ifThe company shares preclinical data. It shows PRT13722 works well in important cancer models.
Worry ifEarly data shows PRT13722 may not work well. There are also safety concerns.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$297 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $1,108 loss on $10,000 · 11.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,010 loss on $10,000 · 70.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Filing the IND is crucial for starting the Phase 1 study in HR+ breast cancer. This step is key for advancing the drug's development.
Supportive ifThe company files the IND application for PRT13722 by mid-2026 as planned.
Worry ifThe IND filing is delayed beyond mid-2026.
Why it matters: Enrollment in this study is a key indicator of the drug's development and market potential. It shows demand and interest in the treatment.
Supportive ifEnrollment numbers in the Phase 1 study of PRT12396 will rise a lot next quarter.
Worry ifEnrollment stalls or decreases in the Phase 1 study of PRT12396.